How effective are lipid lowering drugs in patients with Membranous Nephropathy?
Lipid abnormalities associated with proteinuria are likely important players in the high cardiovascular risk seen in patients with MN and thus provide an important target for treatment.
Statins can improve the lipid profile and reduce cardiovascular morbidity and mortality in patients with chronic kidney disease.
Statins have a synergistic antiproteinuric effect when combined with ACE inhibitors, but this effect is small and mainly observed in patients with proteinuria <3 g/24 hours.
